Objective: To review the evidence for statin secondary prevention of coronary artery disease in patients with near-optimal or optimal low-density lipoprotein cholesterol (LDL-C).
Data Sources: A MEDLINE search (1966-October 2003) was conducted using the search terms HMG-CoA reductase inhibitor, statins, coronary disease, post-myocardial infarction, and average cholesterol.
Data Synthesis: Secondary prevention trials enrolling subjects with near-optimal (<130 mg/dL) or optimal (<100 mg/dL) baseline LDL-C were included. Early statin secondary prevention studies suggested attenuated benefit, but more recent trials challenge this finding.
Conclusions: Statin secondary prevention of coronary artery disease in patients near goal LDL-C is controversial, but recent trial results show promise.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1345/aph.1D166 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Basic Science and Pathogenesis.
Alzheimers Dement
December 2024
University of North Texas Health Science Center, Fort Worth, TX, USA.
Background: The long-term goal of Health & Aging Brain Study - Health Disparities (HABS-HD) is to establish population-specific informed precision medicine for novel treatment and prevention strategies as has been done in other fields. Genomic studies are integral to these efforts and contribute vital data regarding genetic ancestry of the HABS-HD participants, as well as whole genome sequence data, genome-wide genotype (Illumina Global Screening array version 3.0) and epigenetic data (Illumina EPIC DNA methylation array).
View Article and Find Full Text PDFClinical Manifestations.
Alzheimers Dement
December 2024
The George Institute for Global Health, Newtown, NSW, Australia.
Background: Intracerebral hemorrhage (ICH) is the most severe and disabling stroke, accounting for up to 50% of the cases in low-to-middle-income countries. High rates of cognitive decline and dementia follow acute ICH, due to the common underlying vasculopathy of cerebral small vessel disease (CSVD). The international clinical trial, TRIDENT (Triple therapy prevention of Recurrent Intracerebral Disease EveNts Trial), aims to determine the effectiveness of the fixed low-dose Triple Pill combination of blood pressure-lowering agents (telmisartan 20 mg, indapamide 1.
View Article and Find Full Text PDFClinical Manifestations.
Alzheimers Dement
December 2024
Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Background: Vascular-based dementia risk scores (VDRS) which reliably predict risk of Alzheimer's disease and related dementias (ADRDs), may be useful to identify at-risk individuals for secondary prevention trials. Dementia risk scores have typically focused on predicting ADRD-associated symptoms, with fewer studies assessing capacity for detecting individuals with underlying brain pathologies. We compare the predictive value of two vascular-based risk scores (CAIDE and Reitz VDRSs) for discriminating AD-related histopathological and structural abnormalities, further considering race and gender differences.
View Article and Find Full Text PDFClinical Manifestations.
Alzheimers Dement
December 2024
Cognitive Impairment Diagnosis and Dementia Prevention Unit, Peruvian Institute of Neurosciences, Lima, Lima, Peru.
Background: Rising dementia prevalence in Low and Middle-Income Countries (LMICs), fueled by socio-economic disparities, necessitates accessible brief cognitive tests. The INECO Frontal Screening (IFS) proves effective for detection of Mild Cognitive Impairment (MCI) and early dementia. It prioritizes executive functions, is suitable for low-educated or illiterate individuals, and robust diagnostic capacity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!